Business Wire

MA-CENTERITY

22.10.2020 15:02:08 CEST | Business Wire | Press release

Share
Centerity Recognized for Market-Leading AIOps Platform with Integrated Cyber Security

Centerity Systems, Inc. , the leading AIOps Platform with advanced performance analytics and integrated security, today announced its recognition as a Top Value Leader in the latest “EMA Radar Report: AIOps – A Guide for Investing in Innovation .”

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201022005664/en/

EMA evaluated 17 AIOps vendors on (i) Business Impact and IT-to-Business Alignment, (ii) Incident, Performance, and Availability Management, and (iii) Change Impact and Capacity Optimization use cases to guide organizations with their AIOps platform selection. Centerity’s AIOps Platform is designated as a market leader in all of the use cases EMA evaluated. Centerity is a front-runner in delivering exceptional value in both the Business Impact and IT-to-Business Alignment and Incident, Performance, and Availability Management use cases, due to its technical strength, impact on business outcomes, and deployment cost efficiency. In addition, Centerity was honored by EMA with a special award for advanced integrated security functionality.

The Centerity AIOps Platform improves performance and reliability of business and operational processes, employing an approach that continuously measures the overall health of key technology services by providing real-time, consolidated business analytics. SLA executive dashboards expose business and security risks, identify performance anomalies, and provide fault isolation across applications, operating systems, infrastructure and cloud assets. It does this by automating topology and dependency maps of all IT assets, incorporating each asset into business and operational service views. Its AI-driven anomaly detection and multi-tenancy supports multi-user, multi-vendor, and multi-location management, which is ideal for managed service providers, cloud service providers, and enterprises.

“Centerity is a unique innovator in the AIOps arena,” said Dennis Drogseth, EMA vice president. “Centerity stands out for its advancing use of AI/ML in a variety of contexts, including ‘CyberOps,’ as well as its distinctive strengths in discovery across domains, data assimilation, and unifying views and dashboards. These strengths, along with the platform’s fast time to value and limited administrative overhead all help to make Centerity both a versatile and progressive choice for AIOps adopters.” According to EMA’s evaluation, the Centerity AIOps platform is differentiated among its competitors by:

  • Delivering many of the benefits of larger and more costly AIOps suites with reduced administrative overhead and more modest software costs.

  • Bringing the full seven-layer stack together with an eye toward IT service performance and business outcomes and priorities across cloud, hybrid, and legacy environments.

  • Integrating artificial intelligence and machine learning capabilities to support security and risk management needs – such as cybersecurity compliance, endpoint detection and response (EDR), supply chain security, and automated prevention of attacks on network hardware.

According to EMA, the message for IT organizations looking to pursue a forward path in AIOps adoption is overall a strongly positive one. The benefits achieved are growing in diversity and value. AIOps can and should be transformative in enabling more effective decision-making, data sharing, and analytics-driven automation. The recommendation from EMA remains that buyers should consider their own realities, then begin a search for the AIOps platform that most fits their requirements.

“In the digital age, AIOps, security and risk management must be observed and correlated through a single platform,” said Roi Keren, CEO of Centerity Systems. “That’s not only what we see our customers need and want, it’s what Centerity does best. EMA’s positioning of Centerity and award for integrated security acknowledges the convergence of AIOps and security. It’s more critical than ever for enterprise executives – whether you’re a CIO, CISO, CEO, or board member -- to make strategic, risk-based business decisions with one platform, one dashboard; in essence, a single source of truth.”

AIOps Deployments and the Real Word: Bringing Operations and Security Together

Enterprises can see how others are deploying AIOps to address a variety of use cases by viewing a live EMA-hosted webcast titled “AIOps Deployments and the Real World: Bringing Operations and Security Together ,” which will be held on Tuesday, November 10th at 1:00 pm EST. You can register for the webcast at https://info.enterprisemanagement.com/aiops-deployments-in-the-real-world-webinar-centerity .

About Centerity

Centerity’s Cyber-AIOps Platform with advanced Integrated Security delivers Dynamic Business Service Views of the full technology stack to the executives responsible for technology-driven business services, ensuring the performance, availability and security of critical processes. Centerity displays real-time, consolidated business analytics for complex on-prem, cloud, and hybrid technology environments generating SLA Executive Dashboards that identify performance anomalies and isolate faults across applications, operating systems, infrastructure and cloud assets. Learn more at centerity.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release

The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u

Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release

Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata

LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release

LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The

“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release

Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the

Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release

Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye